DNAprint Genomics (DNAG)

[ann441j]

"Press Release Source: DNAPrint Genomics, Inc.

DNAPrint Genomics Receives Patent for Identifying Links Between Gene Sequences and Medical Traits
Tuesday September 19, 2006 7:00 am ET

SARASOTA, FL--(MARKET WIRE)--Sep 19, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that the Company has formally been granted a patent by the U.S. Patent and Trademark Office for Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company's methods for identifying links between gene sequences and phenotypes (physical or medical traits), and follows a Notice of Allowance for the process in April of this year.

"It is important to protect the company's technologies and the revenue that can be derived from them," stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Our proprietary methods for marking gene sequences are especially important, because they are the key to developing theranostic drugs."

The patent provides legal protection for DNAPrint's status as one of few companies currently capable of performing objective, assumption-free haplotype analysis of DNA strands.

DNAPrint Genomics currently holds two other patents and has several others pending or in the hands of patent counsel.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Ann